· Decision aids enhance shared decision-making, reduce anxiety, and improve understanding of treatment options.
· Patients value personalized support and clear communication with doctors, but preferences vary (some want detailed info, while others prefer less).
· Tools like brochures or videos can help patients and families, but must avoid adding confusion.
Read more here: https://lnkd.in/dAfqAsfY
Our manuscript “Cost-effectiveness models of non–small cell lung cancer: A systematic literature review” is now available in the Journal of Managed Care & Specialty Pharmacy. This work, developed by our economic partner IHE – The Swedish Institute for Health Economics, marks a significant step in understanding cost-effectiveness models in non-small cell lung cancer.
Thank you to the authors for their effort and dedication:
– Michael Willis, PhD
– Andreas Nilsson, MSc
– Zin Min Thet Lwin, MSc
– Gunnar Brådvik, MSc
– Arsela Prelaj, MD, PhD
Read the full article here: https://lnkd.in/dqUjSp7Z
Michael Willis, from the IHE – The Swedish Institute for Health Economics attended the 2024ISPOR conference in Barcelona this week to present a poster titled “Are 237 Published Cost-Effectiveness Models Necessary for Non-Small-Cell Lung Cancer (NSCLC)? Can Open Source “Model Platforms” Improve Decision-Making and Save Resources?”
Briefly, the poster compares some key characteristics of the identified cost-effectiveness models and tries to answer whether so many unique models are motivated, and explore potential benefits that might accrue if open-source models were made available.
I3LUNG was featured at the ESMO – European Society for Medical Oncology, held from September 13 to 17 in Barcelona.
The poster titled: “Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy” was presented by our PI, Dr. ArselaPrelaj, on September 14th at 11 AM. Additionally, the poster was available for viewing throughout the day, from 9 AM to 5 AM.
Take a look to the I3LUNG poster:
We invite you to watch the video shares more details about our project.
Michael Willis and his team at IHE – The Swedish Institute for Health Economics, have published a groundbreaking article in the Journal of Managed Care & Specialty Pharmacy: “Budget Impact Models for Lung Cancer Interventions: A Systematic Review of the Literature.” This study provides an in-depth perspective on the financial implications of new lung cancer treatments and highlights the need for more accurate and transparent economic evaluations.
In their review of 25 budget impact models (BIMs) for non-small cell lung cancer interventions, the article emphasizes the importance of having rigorous BIMs to guide resource allocation and reimbursement decisions in an ever-evolving landscape. 📊💡
Learn more about this research, which is part of the I3LUNG project, and how it aims to improve patient outcomes through AI-driven decision-making tools.
Link to full paper 👉🏼 https://www.jmcp.org/doi/10.18553/jmcp.2024.30.9.1041
I3LUNG project has been featured in Nature Portfolio, one of the world’s most prestigious scientific platforms.
In this article, Arsela Prelaj, PI of the study from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, provides an in-depth and insightful interview on the impact and advancements of the I3LUNG project. The article, titled “Therapy selection gets AI assistance,” was skillfully written by Michael Eisenstein, who has expertly captured how I3LUNG is revolutionizing therapy selection in oncology with the help of artificial intelligence.
This report also highlights valuable contributions from other oncology and AI experts, emphasizing the importance and innovation that this project brings to the field of cancer research.
To read the full article, click on the following link: Therapy selection gets AI assistance
We are proud to share our latest study in Cancer Medicine journal led by our partner IEO Istituto Europeo di Oncologia: “The impact of decision tools during oncological consultation with lung cancer patients: A systematic review”.
To date, lung cancer is one of the most lethal diagnoses worldwide. A variety of lung cancer treatments and modalities are available, which are generally presented during the patient and doctor consultation. The implementation of decision tools to facilitate patient’s decision-making and the management of their healthcare process during medical consultation is fundamental. Studies have demonstrated that decision tools are helpful to promote health management and decision-making of lung cancer patients during consultations. The main aim of the present work within the I3LUNG project is to systematically review the implementation of decision tools to facilitate medical consultation about oncological treatments for lung cancer patients.
For more information about I3LUNG, visit the Project website or contact us.
Read the Cancer Medicine article!
We are pleased to announce that the study design of the I3LUNG project has just been published in the journal Clinical Lung Cancer.
The publication explains the I3LUNG study design and marks the beginning of a series of publications that will dig into the project’s groundbreaking work. Subsequent articles will detail the specific areas within the I3LUNG consortium and provide updates on results related to this comprehensive project’s different aspects.
The I3LUNG initiative is led by Dr. Arsela Prelaj, Medical Oncologist at Istituto Nazionale dei Tumori of Milan, and is a collaborative effort involving 16 partners located worldwide. Funded under the Horizon Europe Program framework, the project is focused on “Ensuring access to innovative, sustainable, and high-quality healthcare.” It will cover a 5-year timeframe, from 1st June 2022 to May 2027.
Due to its poor prognosis and limited therapeutic options, there is a large unmet need for patients with metastatic non-small cell lung cancer (mNSCLC). I3LUNG aims to develop a platform that utilizes artificial intelligence and machine learning tools to predict an mNSCLC patient’s response to immunotherapy according to their clinical characteristics. The platform will combine data collected from the medical records of patients who are candidates for immunotherapy. It will then study each individual’s response to treatment while leveraging the expertise of the different partners, ranging from imaging to omics sciences.
The I3LUNG project represents a major stride towards personalized medicine and, therefore, the integrated management of mNSCLC patients. While immunotherapy can harness the power of the immune system to fight cancer, it is a costly treatment that, unfortunately, may not benefit all patients especially considering the frequency of adverse events registered. This project aims to better assist mNSCLC patients and physicians in selecting the right treatment by developing an algorithm capable of predicting the patient’s response to immunotherapy and integrating those medical considerations as well as the individual’s treatment preferences. More efficient treatment of mNSCLC patients will enhance their quality of life and alleviate the economic strain on the European healthcare system.
The I3LUNG project sets hope on the horizon for mNSCLC patients, as it aims to deliver the right therapy to the right patient at the right time, thereby assisting physicians in making therapeutic decisions and patients in undergoing more conscious treatment journeys. We are enthusiastic about our involvement in this remarkable initiative, which has the potential to revolutionize lung cancer therapy.
For more information about I3LUNG, visit the Project website or contact us.